TY - JOUR AU - Okabe, Kazunori PY - 2017 TI - Intraoperative intracavitary hyperthermic chemotherapy for malignant pleural mesothelioma JF - Annals of Translational Medicine; Vol 5, No 11 (June 15, 2017): Annals of Translational Medicine (Focus on “Mesothelioma”) Y2 - 2017 KW - N2 - Malignant pleural mesothelioma (MPM) is a dreadful disease with a poor prognosis. Multimodality therapy including surgical macroscopic complete resection is performed to treat operable MPM. Intraoperative intracavitary hyperthermic chemotherapy for MPM was reviewed. Appropriate papers published between 2006 and present were extracted by the PubMed advanced search by MPM (Title/Abstract), chemotherapy (Title/Abstract), and hyperthermia (All fields). Among the selected papers, those written in English, and treated more than ten MPM patients were reviewed. The intraoperative intracavitary hyperthermic chemotherapy has been performed following extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D) for MPM. Cisplatin was mainly used for perfusion, and the morbidity and mortality was acceptable. In conclusion, the intraoperative intracavitary hyperthermic chemotherapy following EPP or P/D for MPM might enhance local control in the chest cavity. UR - https://atm.amegroups.org/article/view/14450